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Abstract
Background: Pharmaceutical representatives provide medicines information on their promoted products to
doctors. However, studies have shown that the quality of this information is often low. No study has assessed the
medicines information provided by pharmaceutical representatives to doctors in Malaysia and no recent evidence
in Australia is present. We aimed to compare the provision of medicines information by pharmaceutical
representatives to doctors in Australia and Malaysia.
Methods: Following a pharmaceutical representative’s visit, general practitioners in Australia and Malaysia who had
agreed to participate, were asked to fill out a questionnaire on the main product and claims discussed during the
encounter. The questionnaire focused on provision of product information including indications, adverse effects,
precautions, contraindications and the provision of information on the Pharmaceutical Benefit Scheme (PBS) listings
and restrictions (in Australia only). Descriptive statistics were produced. Chi-square analysis and clustered linear
regression were used to assess differences in Australia and Malaysia.
Results: Significantly more approved product information sheets were provided in Malaysia (78%) than in Australia
(53%) (P < 0.001). In both countries, general practitioners reported that indications (Australia, 90%, Malaysia, 93%) and
dosages (Australia, 76%, Malaysia, 82%) were frequently provided by pharmaceutical representatives.
Contraindications, precautions, drug interactions and adverse effects were often omitted in the presentations (range
25% - 41%). General practitioners in Australia and Malaysia indicated that in more than 90% of presentations,
pharmaceutical representatives partly or fully answered their questions on contraindications, precautions, drug
interactions and adverse effects. More general practitioners in Malaysia (85%) than in Australia (60%) reported that
pharmaceutical representatives should have mentioned contraindications, precautions for use, drug interaction or
adverse effects spontaneously (P < 0.001). In 48% of the Australian presentations, general practitioners reported the
pharmaceutical representatives failed to mention information on PBS listings to general practitioners.
Conclusions: Information on indications and dosages were usually provided by pharmaceutical representatives in
Australia and Malaysia. However, risk and harmful effects of medicines were often missing in their presentations.
Effective control of medicines information provided by pharmaceutical representatives is needed.
Background
Global pharmaceutical sales in 2008 were estimated at
US$ 773 billion [1]. Sales growth has nearly doubled
since 2001 [1]. Pharmaceutical companies secure their
market share by using promotional techniques,
including pharmaceutical detailing. Concerns have been
raised about the quality of medicines information pro-
vided by pharmaceutical representatives to doctors, with
studies consistently showing that benefits of medicines
are promoted and risk information is less commonly
provided [2-4].
In 1997, a systematic review [5] found four studies
that examined medicines information provided by phar-
maceutical representatives to doctors in three developed
countries; Finland, the US and Australia. In Finland, two
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representatives in hospitals and outpatient clinics were
published in 1977 [2] and 1988 [6] respectively. Medical
students and doctors acted as participant observers and
filled out questionnaires after the interactions [2,6]. In
both studies, indications (range per study 90-94%) and
generic names (range per study 62-78%) were usually
mentioned by pharmaceutical representatives. However,
side effects (range per study 27-41%) and contraindica-
tions were less frequently provided (range per study 25-
34%).
In 1995, statements made by pharmaceutical represen-
tatives during 13 presentations to medical students and
doctors in teaching hospitals in the US were audiotaped
and analysed for accuracy [3]. Eleven percent of 106
statements were rated inaccurate and provided a favour-
able impression towards the promoted drug [3]. An
Australian study audiotaped and analysed 16 detailing
presentations from December 1992 to February 1994
[4]. Adverse effects were mentioned in 27% of the pre-
sentations, contraindications were never mentioned, and
use in pregnancy was only mentioned on one occasion.
Information on adverse reactions appeared to be asso-
ciated with claims aimed at minimizing the apparent
risk associated with product use rather than detailing
the possible adverse effects [4].
A survey in France from 1991 to 2005 used a network
of doctors to monitor pharmaceutical representatives’
presentations [7]. Doctors were recruited from among
La revue Prescrire’s subscribers and completed question-
naires after sales detailing by pharmaceutical representa-
tives. Consistent results were noted in the 15 year
survey. Indications were commonly provided (range per
year, 64-81%) by pharmaceutical representatives. How-
ever, contraindications, precautions, drug interactions
and side effects were less frequently mentioned (range
per year, 9-35%) [7].
Despite differences in methodology, the results of all
these studies [2-4,6,7] suggest that pharmaceutical
representatives did not provide balanced medicines
information to doctors. Indications and generic names
were commonly mentioned, but risk information was
often omitted.
In Australia, the interactions between pharmaceutical
representatives and doctors are governed by the phar-
maceutical companies association, Medicines Australia
Code of Conduct [8], which complements the standards
set by the Australian government Therapeutic Goods
Act 1989 [9]. Likewise, in Malaysia, pharmaceutical
representatives’ activities are controlled by the Pharma-
ceutical Association of Malaysia (PhAMA) Code of Con-
duct [10] and comply with the requirements of the
Medicine (Advertisement and Sale) Act 1956. Both
codes require that provision of medicines information
made by pharmaceutical representatives be balanced,
accurate, correct, fully supported by the product infor-
mation, literature or data on file or appropriate industry
sources, where these do not conflict with the product
information [8,10].
Pharmaceutical representatives in Australia and
Malaysia are required to have sufficient medical and
technical knowledge to present information on the com-
pany’s products in a current, accurate and balanced
manner [8,10]. Medicines Australia requires that all
pharmaceutical representatives complete an endorsed
Medicines Australia education program for medical
representatives [8]. In Malaysia, pharmaceutical repre-
sentatives need to obtain a minimum educational level
of a Sijil Tinggi Pelajaran Malaysia (equivalent to year
12)[11]. Additionally, PhAMA offers non-compulsory
training for pharmaceutical representatives [12]. In both
countries, the regulation of pharmaceutical representa-
tives’ activities is based on a complaints mechanism
[8,10]. Neither Medicines Australia nor PhAMA proac-
tively monitor pharmaceutical representatives’ activities
[8,10].
In 1986, The 39th World Health Assembly called on
governments to implement a National Medicinal Drug
Policy [13]. Many countries, including Australia [14] and
Malaysia, have developed national medicines policies
[13,14]. The national medicines policies provide a phar-
maceutical system framework to ensure equitable and
timely access to high quality medicines to support
rational use of medicines. In both countries, health care
is delivered by private and government sectors. In
Australia, the government heavily subsidizes medicines in
both sectors through the Pharmaceutical Benefits
Scheme (PBS) and the Repatriation Pharmaceutical Bene-
fits Scheme (RPBS) [15]. The consumers pay a propor-
tion of total costs out of pocket. In Malaysia, medicines
in the public health care services are subsidized by the
government with minimum fees being charged to the
public, whereas in the private sector patients are required
to pay full price for their medications [16,17]. However,
compared to Australia, several aspects of the Malaysian
national medicine policy have not been implemented yet.
In particular, there has been no public examination,
either by non-governmental or governmental organisa-
tions, of the success of the current regulatory system in
controlling pharmaceutical promotion. In Australia, sev-
eral studies have assessed the quality of pharmaceutical
promotion over time [4,18-20]. Watchdog organisations
such as Healthy Skepticism and CHOICE are repeatedly
raising concerns about misleading drug promotion
[21,22] and the adequacy of Medicines Australia’sc o d e
of conduct is reviewed regularly by the Australian Com-
petition and Consumer Commission to ensure compli-
ance with the Australian Trade Practices Act [23].
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From 1985 to 2007 a total of 175,746 products were
approved by the Malaysian Drug Control Authority [24].
This has made the market more competitive [25] and
pharmaceutical companies appear to be heavily promot-
ing their medicines to Malaysian health professionals
[26]. Given the absence of a comprehensive independent
source of prescribing information in Malaysia, Malaysian
doctors may be more likely to rely on medicines infor-
mation provided by pharmaceutical companies.
To our knowledge, no study has assessed the quality
of medicines information provided by pharmaceutical
representatives to doctors in Malaysia and there is no
recent evidence from Australia. We aimed to compare
the quality of medicines information provided by phar-
maceutical representatives to doctors in Australia and
Malaysia, in particular the provision of information on
potential harmful effects of a medicine including contra-
indications, precautions, drug interactions and adverse
effects.
Methods
This study was a prospective observational study of doc-
tor-pharmaceutical representatives’ encounters. It was
conducted from 15/8/07 to 15/4/2009 (20 months).
Doctors in primary care settings in Australia and
Malaysia, who met pharmaceutical representatives in
their regular practice and were practicing at least
25 hours per week during the study period, were invited
to participate. This study was approved by the Human
Research Ethics Committee of the University of South
Australia, the Universiti Sains Malaysia (USM) and the
Universiti Kebangsaan Malaysia (UKM).
Doctors were asked to monitor four to ten encounters
with pharmaceutical representatives. A doctor-pharma-
ceutical representative encounter was defined as one
meeting between doctor(s) and pharmaceutical repre-
sentative(s) which happened at the doctor’s surgery.
Both one-on-one and group presentations were
assessed. The meeting was based on an appointment
and had to be longer than one minute. “Corridor” meet-
ings with pharmaceutical representatives were not con-
sidered suitable for this study. Doctors were encouraged
to see as many pharmaceutical representatives during
the study period as usual.
Sample size calculation
La Revue Prescrire, which organised a pharmaceutical
representatives’ monitoring network in France for 15
years, reported that on average, adverse effects were
mentioned in 32% of sales representatives’ promotional
presentations [27]. In this study, an absolute difference
between pharmaceutical sales detailing in Malaysia and
Australia of 20% in the availability of information on
particular adverse effects was considered a substantive
difference. A sample size of 66 encounters per study
arm would detect this degree of difference with 80%
power at a = 0.05.
In Canada, it has been reported that doctors received
a mean of 5.6 visits per month from sales representa-
tives (range 0-28) and a mean of 2.2 products per visit
[28]. This study assumed a similar situation in Australia
and Malaysia. If doctors recorded information on four
presentations, a sample size of 20 doctors per study arm
would provide 80 observations. Data collection could be
completed within four to five weeks per physician.
Recruitment of general practitioners
Australia
Two mechanisms were employed to recruit doctors in
Australia.
Eleven divisions of general practices in different states
of Australia contacted general practitioners on our
behalf. These organizations are members of the network
of Australian Divisions of General Practice and funded
by the Australian Government Department of Health
and Ageing [29].
Doctors who were Healthy Skepticism [21] subscribers
( H S S )w e r ei n v i t e dt op a r t i c i p a t ei nt h es t u d ya n dt o
nominate two doctors who could also be willing to par-
ticipate. The nominated doctors were also invited to
participate. Healthy Skepticism is an international non-
profit organisation aiming to improve health by redu-
cing harm from misleading drug promotion [21]. This
organisation uses research, education and advocacy to
improve drug promotion by the pharmaceutical indus-
try. Healthy Skepticism subscribers have an interest in
research on pharmaceutical promotion and were consid-
ered more likely to participate in the study.
Malaysia
In Malaysia, primary care treatment to the public is pro-
vided by three different types of doctors. These are gen-
eral practitioners in private clinics, family medicine
doctors who are undergoing specialist training in teach-
ing hospitals, and family medicine specialists in teaching
hospitals or private clinics. All types of primary care
providers were included in this study.
Doctors from family medicine departments in two
teaching hospitals in Malaysia, Universiti Sains Malaysia,
Kota Bharu (USM), Universiti Kebangsaan Malaysia,
Kuala Lumpur (UKM), general practitioners in private
practices in Kota Bharu and Kuala Lumpur were invited
to participate in this study.
Doctors who agreed to participate were asked to
nominate two general practitioners from private practice
who could also be willing to participate in this study.
The nominated doctors were also invited to participate
in the study.
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invited its members in rural and urban areas to partici-
pate in the study. MMA is a professional body repre-
senting Malaysian doctors, which focuses its activities
on enhancing healthcare in Malaysia.
All doctors from the Australian and Malaysian lists
were invited to participate in this study by a letter or an
email. We invited 3038 doctors in Australia and 819
doctors in Malaysia.
Of 3038 Australian doctors that were invited, 2955
were contacted by general practitioner divisions, 70 by
Healthy Skepticism and 13 via nominations from general
practitioners. In Malaysia, 119 general practitioners were
invited from family medicine departments, while 694
were contacted via MMA and six were invited based on
recommendations from general practitioners. A reply
letter with a prepaid envelope was attached to the invi-
tation letter. A follow up letter or email was sent if no
reply was received within two weeks. In Australia, we
posted a brief advertisement in the newsletter provided
by the South Australia Divisions of General Practice Inc.
to 1738 general practitioners in the divisions.
An information sheet was sent to doctors who had
agreed to participate in the study. Participating doctors
were asked to provide personal details on gender, age,
years in practice, postgraduate qualifications, number of
doctors in practice and average number of pharmaceuti-
cal representatives met every week. Each doctor was
assigned an identifying code. Pharmaceutical representa-
tives were made aware of the study and were asked for
consent to participate. Only doctors were allowed to get
written consent from pharmaceutical representatives.
Following a pharmaceutical representative’s visit, doc-
tors filled out a questionnaire focusing on the main pro-
duct and claims discussed during the encounter. The
main product refers to the product that was approved
by the authorities to be marketed and was given most
attention by the pharmaceutical representative in a sin-
gle encounter. Doctors were required to report their
own assessment of the prescribing frequency of the pro-
ducts promoted. The questionnaire focused on provision
of product information, including indications, adverse
effects, precautions, contraindications and the provision
of information on the listing of a medicine on the Phar-
maceutical Benefit Scheme (PBS), the Australian public
insurance scheme [31]. “New medicine” was defined as a
medicine that general practitioners believed would be
marketed soon or had been marketed recently. “Old
medicine” referred to a medicine that general practi-
tioners believed had been marketed for a period of time.
Doctors were asked to keep the completed question-
naires in a secure place and send them to the research-
ers every two weeks in a prepaid reply envelope. The
questionnaire was based for its major part on
questionnaires developed in previous studies [4,7,32].
The face validity of the questionnaire was assessed by
six experts in the field of study and doctors in Australia,
Malaysia and Canada. The questionnaire was then modi-
fied based on their comments.
Data entry was undertaken using SPSS database ver-
sion 17.0. Chi-square analysis was used to assess differ-
ences in the provision of product information given by
pharmaceutical representatives to doctors in Australia
and Malaysia. As there were multiple observations for
each general practitioner, additional clustered linear
regression was conducted with STATA 10 to assess if
doctors reported information provided to them differ-
ently. The Bonferroni correction for multiple compari-
sons was applied.
Results
A total of 89 general practitioners agreed to participate
into the study and 34 returned 183 completed ques-
tionnaires (Figure 1). More general practitioners agreed
to participate and returned completed questionnaires
in Malaysia than in Australia. In Malaysia, from 127
returned questionnaires, two were excluded, as the
main products detailed were a baby milk formula and
a fermented milk drink. In Australia, of 10 general
practitioners who returned the completed question-
naires, three of them were Healthy Skepticism mem-
bers. On average, each general practitioner completed
six and five questionnaires in Australia and Malaysia
respectively.
Australian and Malaysian general practitioners were
aged 45-54 years old (70%) and 35-44 years old (50%)
respectively (Table 1). The majority of Australian (70%)
and Malaysian (75%) general practitioners had postgrad-
uate qualifications and met one to three pharmaceutical
representatives every week. The majority of general
practitioners in Australia (60%) and all general practi-
tioners in Malaysia practiced in urban locations.
A total of 45 and 84 main medicines were discussed in
pharmaceutical representatives’ presentations in Australia
and Malaysia respectively. The most frequently promoted
medicines in both countries were for cardiovascular dis-
eases. More new medicines were discussed in Malaysia
t h a ni nA u s t r a l i a( P<0 . 0 0 1 )( T a b l e2 ) .T h em a j o r i t yo f
presentations in both countries were personal presenta-
tions (Australia, 98%, Malaysia, 98%).
When old medicines with new information or indica-
tions were presented, the majority of general practi-
tioners in Australia (61%) and Malaysia (52%) reported
being medium users of the products. In all presentations
where a medicine was classified as “new”, general practi-
tioners in both countries reported that they were non
users. About half of discussions lasted from five to ten
minutes (Australia, 52%, Malaysia, 44%).
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in more than half of the presentations (Australia, 53%,
Malaysia, 78%), and more commonly in Malaysia than
in Australia (P < 0.001) (Table 3).
In both countries, general practitioners reported that
information on indications (Australia 90%, Malaysia
93%) and dosages (Australia 76%, Malaysia, 82%) was
frequently given by pharmaceutical representatives for
all types of products discussed (Table 3 and 4). General
practitioners indicated that information on negative
aspects such as contraindications, precautions, drug
interactions and adverse effects (Australia 41%, Malaysia
36%) was less commonly provided. However, this infor-
mation was provided more frequently for new medicines
than for old medicines.
The clustered regression analysis found similar results to
the chi square analysis: there were no significant differences
between countries regarding the availability of medicines
information on indications (p = 0.69), dosages (p = 0.32),
contraindications (p = 0.38), precautions (p = 0.53), drug
interactions (p = 0.24) and adverse effects (p = 0.35).
The comparison of the provision of medicines infor-
mation reported by Healthy Skepticism subscribers
(HSS) and non-subscribers (HNS) suggested different
trends. Reports on provision of medicines information
on indications (HSS 89%, HNS 90%, p = 0.94), dosages
(HSS 56%, HNS 79%, p = 0.12) and contraindications
(HSS 22%, HNS 36%, p = 0.42) were not significantly
different. However, Healthy Skepticism subscribers
reported that information on precautions (HSS 0%, HNS
46%, p = 0.01), interactions (HSS 0%, HNS 40%, p =
0.02), and adverse effects (HSS 11%, HNS 48%, p =
0.04) was less likely to be provided by pharmaceutical
representatives than non Healthy Skepticism providers.
General practitioners in Australia and Malaysia indicated
that in more than 90% of presentations, pharmaceutical
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Figure 1 Recruitment and participation of general practitioners.
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contraindications, precautions, drug interactions and
adverse effects. More general practitioners in Malaysia
(85%) than in Australia (60%) reported that pharmaceutical
representatives should have mentioned contraindications,
precautions for use, drug interaction or adverse effects
spontaneously (P < 0.001).
Overall, about half of the presentations did not include
any information on potential harm of the medicine, such
as adverse effects, interactions or contraindications
(Australia 50%, Malaysia, 46%). Of the presentations
where negative effects were missing, pharmaceutical repre-
sentatives provided approved product information sheets
in about half of the presentations (Australia, 41% Malaysia,
68%). Information on harm was missing in more than one-
third of presentations in which general practitioners
believed pharmaceutical representatives should have men-
tioned it (Australia, 34%, Malaysia 41%). Approximately
one-fifth of general practitioners in both countries
(Australia 22%, Malaysia 16%, p = 0.13) did not ask phar-
maceutical representatives any questions on contraindica-
tions, precautions, drug interactions or adverse effects.
In 48% of the Australian presentations, general practi-
tioners reported the pharmaceutical representatives
failed to mention information on PBS listings to them.
Discussion
Similar trends in the provision of medicines information
by pharmaceutical representatives were reported by gen-
eral practitioners in Australia and Malaysia. Information
on indications and dosages was usually provided in
pharmaceutical representatives’ presentations. However,
contraindications, precautions, drug interactions and
adverse effects were often missing in both countries.
The imbalance of medicines information provided by
pharmaceutical representatives is consistent with the
Table 1 Characteristics of general practitioners
Characteristics Australia n/10 (%) Malaysia n/24 (%)
Gender Male 5 (50) 14 (58)
Female 5 (50) 10 (42)
^P = 0.85
Age < 35 years 0 3 (13)
35-44 years 1 (10) 12 (50)
45-54 years 7 (70) 7(29)
> 54 years 2 (20) 2 (8)
^P = 0.01
Years in practice Less than 5 years 1 (10) 3 (12)
5-10 years 0 5 (21)
10-20 years 4 (40) 12 (50)
Over 20 years 5 (50) 4 (17)
^P = 0.02
Postgraduate qualifications Fellowship and postgraduate 6 (60) 8 (33)
Fellowship only 2 (20) 0
Postgraduate only 1 (10) 10 (42)
None 1 (10) 6 (25)
^P = 0.02
Site of practice Urban 6 (60) 24 (100)
Rural 4 (40) 0
^P = 0.001
Number of doctors in practice 1 0 8 (33)
2-5 doctors 6 (60) 4 (17)
More than 5 doctors 4 (40) 12 (50)
^P = 0.03
Average number of pharmaceutical representatives met every week 1-3 7 (70) 14 (58)
4-6 3 (30) 10 (42)
^P = 0.09
^ P-value (Comparison Australia and Malaysia).
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question of the effectiveness of the existing regulatory
systems to oversee medicines information provided by
pharmaceutical representatives. In both countries, unlike
for printed advertisements, the requirements set by the
pharmaceutical companies’ codes of conduct on the pro-
vision of medicines information by pharmaceutical
representatives are vague [8,10]. Medicines Australia
and PhAMA codes of conduct require that printed
advertisement on medicines must disclose the properties
of medicines based on the approved product informa-
tion. For instance, printed advertisements shall include
information on dosages, indications, side effects, contra-
indications and precautions [8,10]. No similar provision
is available for verbal statements made by pharmaceuti-
cal representatives [8,10].
The lack of difference in quality of information pro-
vided between Australia and Malaysia may seem surpris-
ing, as it could have been expected that the enforcement
of the regulation of pharmaceutical promotion would be
stronger in Australia than in Malaysia. However, unlike
other promotional activities, presentations done by
pharmaceutical representatives are not monitored by
Medicines Australia.
Australian general practitioners reported that
approved product information sheets were not provided
in about half of the presentations, despite it being a
requirement of Medicines Australia that wherever a pro-
motional claim is made, pharmaceutical representatives
must offer the current approved product information
sheets, or make reference to them in any printed pro-
motional provided [8]. Although it is not required by
the PhAMA code of conduct [10], the approved product
information was provided voluntarily by Malaysian phar-
maceutical representatives more often than in Australia.
The proportion of general practitioners that think
pharmaceutical representatives should have mentioned
information on harm spontaneously was higher in
Malaysia (85%) than in Australia (60%), and also higher
than reported in France (77%) [7]. This may reflect
higher needs of Malaysian practitioners, who may
have less ready access to medicines information than
Australian or French practitioners.
The incompleteness of medicines information pro-
vided by pharmaceutical representatives in Malaysia is
of concern. As no comprehensive independent source
of medicines information is available in Malaysia, the
government needs to proactively develop suitable and
effective services to provide independent medicines
information to doctors. The provision of an independent
information service by the National Prescribing Service
(NPS) [33] in Australia could be a model for Malaysia.
NPS is an independent, non-profit organisation funded
by the Australian government which provides doctors
with educational materials on medicines and organised
academic detailing visits [33]. Although the program is
small in comparison to the large amount of money
spent in pharmaceutical promotion [34,35], evidence has
shown that such activities provide savings on govern-
ment spending on medicines [36], improve prescribing
Table 2 Presentations details
Variables Details Australia n/58 (%) Malaysia n/125 (%)
Type of main product discussed New medicine 9 (16) 41 (33)
Old medicine with new information/indication 18 (31) 54 (43)
Old medicine with general information 31 (53) 30 (24)
^ P < 0.001
Type of presentation Personal 50 (86) 122 (98)
Group 8 (14) 3 (2)
^ P = 0.01
Current usage of the main product Low* 14 (24) 33(26)
Medium
& 26 (44) 43 (34)
High# 9 (16) 8 (7)
Non user** 9 (16) 41 (33)
^ P = 0.03
Length of discussion 1-5 minutes 16 (27) 42 (33)
> 5-10 minutes 30 (52) 55 (44)
> 10-20 minutes 10 (18) 26 (21)
> 20 minutes 2 (3) 2 (2)
^ P = 0.65
* Low = rarely used,
&Medium = seldomly used, # High = commonly used, **Non user = never used, ^ P-value (Comparison Australia and Malaysia).
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omission of essential prescribing information in pharma-
ceutical representatives’ presentations in Australia, high-
lights the need for doctors to rely more on independent
sources of information.
We noted that information on the negative effects of
medicines was provided more frequently for new
medicines than for old medicines. However, the small
sample size limits the statistical power of the compari-
son between types of medicines. The results have to be
confirmed with a larger study.
In this study, we actively asked representatives for
consent. This may have led to the pharmaceutical repre-
sentatives changing their behaviour. However, we
Table 3 Provision of information
Information Australia n/
58 (%)
Malaysia n/
125 (%)
Approved product information sheet given Yes 31 (53) 97 (78)
No 27 (47) 28 (22)
^P < 0.001
Indications Yes 52 (90) 116 (93)
No 6 (10) 7 (5)
Unsure 0 2 (2)
^*P = 0.33
Dosage Yes 44 (76) 103 (82)
No 14 (24) 22 (18)
^P = 0.30
Contraindications Yes 19 (33) 50 (40)
No 37 (64) 72 (58)
Unsure 2 (3) 3 (2)
^*P = 0.37
Precautions Yes 21(36) 38 (30)
No 34 (59) 82 (66)
Unsure 3 (5) 5 (4)
^*P = 0.40
Drug interactions Yes 19 (33) 31 (25)
No 38 (65) 89 (71)
Unsure 1 (2) 5 (4)
^*P = 0.30
Adverse effects Yes 24 (41) 45 (36)
No 33 (57) 73 (58)
Unsure 1 (2) 7 (6)
*P = 0.61
Did the representative answer your questions on contraindications, precautions, drug interactions,
adverse effects?
Yes 34/45 (76) 60/105 (57)
No 2/45 (4) 7/105 (7)
Partly 9/45 (20) 38/105 (36)
No question
asked
13 20
^
&P = 0.10
Given the nature of the drug detailed, do you think the representative should have mentioned
contraindications, precautions for use, drug interaction or adverse effects spontaneously?
Yes 35 (60) 106 (85)
No 23 (40) 19 (15)
^P < 0.001
*Chi square test for questions that included variable “unsure” was calculated based on categorical variables “Yes” and “No” only.
&Chi square test for a question with a variable “no question asked” was calculated based on categorical variables “Yes”, “No” and “Partly” only.
^ P-value (Comparison Australia and Malaysia).
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led to pharmaceutical representatives improving their
presentations. Our findings that risk information was
not presented suggest the bias may be limited. The
requirement to get informed consent from pharmaceuti-
cal representatives may have limited participation in our
study. We found that less than a quarter of Australian
general practitioners who agreed to participate in the
study returned the completed questionnaires. Among
the 31 doctors who agreed to participate in the study,
b u td i dn o tr e t u r na n yc o m p l e t e dq u e s t i o n n a i r e s ,m o r e
than half indicated that all pharmaceutical representa-
tives declined to sign the consent form.
The validity of our results may be limited by the small
sample size. The sample of general practitioners who par-
ticipated in this study was not taken randomly from the
population and the results might not be generalisable to
all Australian and Malaysian doctors. Our findings were
based on general practitioners’ self reporting, which is
also subject to bias in recall, however, the surveys were
completed immediately after the encounter, so recall bias
should have been limited. The generalisability of the
Table 4 Provision of information for type of main product discussed
Information New
medicine
Old medicine with new information/
indication
Old medicine with general
information
Type of product Australia
n/9 (%)
Malaysia
n/41 (%)
Australia
n/18 (%)
Malaysia
n/54
(%)
Australia
n/31 (%)
Malaysia
n/30
(%)
Indications Yes 8 (89) 39 (96) 17 (94) 49 (91) 27 (87) 28 (93)
No 1(11) 1(2) 1 (6) 4 (7) 4 (13) 2 (7)
Unsure 0 1(2) 0 1 (2) 0 0
^*P = 0.72
&*P = 0.56
Dosage Yes 7 (78) 35 (85) 14 (78) 45 (83) 23 (74) 23 (77)
No 2 (22) 6 (15) 4 (22) 9 (17) 8 (26) 7 (23)
^P = 0.95
&P = 0.62
Contraindications Yes 5 (55) 24 (59) 4 (22) 20 (37) 10 (32) 6 (20)
No 3 (33) 17 (41) 13 (72) 32 (59) 21 (68) 23 (77)
Unsure 1 (12) 0 1 (6) 2 (4) 0 1 (3)
^*P = 0.15
&*P = 0.01
Precautions Yes 4 (45) 17 (41) 5 (28) 14 (26) 12 (39) 7 (23)
No 4 (45) 23 (57) 12 (66) 38 (70) 18 (58) 21 (70)
Unsure 1 (12) 1 (2) 1 (6) 2 (4) 1 (3) 2 (7)
^*P = 0.59
&*P = 0.19
Drug interactions Yes 5 (55) 16 (39) 3 (16) 11 (20) 11 (35) 4 (13)
No 4 (45) 23 (56) 14 (78) 41 (76) 20 (65) 25 (84)
Unsure 0 2 (5) 1 (6) 2 (4) 0 1 (3)
^*P = 0.14
&*P = 0.02
Adverse effects Yes 6 (67) 23 (57) 7 (39) 16 (30) 11 (35) 6 (20)
No 3 (33) 17 (41) 11 (61) 34 (63) 19 (62) 22 (73)
Unsure 0 1 (2) 0 4 (7) 1 (3) 2 (7)
^*P = 0.26
&*P = 0.01
*Chi square test for questions that included variable “unsure” was calculated based on categorical variables “Yes” and “No” only.
^ P-value (Comparison between type of products: Australia).
& P-value (Comparison between type of products: Malaysia).
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Page 9 of 11findings was also limited by the low response rate. The
f i n d i n g sm a yo n l yb ea p p l i c a ble to interactions between
general practitioners and pharmaceutical representatives
and could not be generalized to other specialties.
Healthy Skepticism subscribers involved in the study
m a yb em o r ec r i t i c a lo ft h eq u a l i t yo fi n f o r m a t i o np r o -
vided by pharmaceutical representatives than other gen-
eral practitioners. More sceptical general practitioners
might be less easily convinced, asked pharmaceutical
representatives’ for more information; and recalled and
reported the information in a different way. None of the
general practitioners in Australia and 42% in Malaysia
were from the same practices. Clustering within the prac-
tices could has affected the findings noted in Malaysia.
Given all Malaysian general practitioners who partici-
pated in the study were practicing in urban areas, our
results could not be generalized to doctors in rural areas
in Malaysia.
We only asked doctors to report the provision of
approved product information sheets to them. In Austra-
lia, approved product information may be included in
promotional materials given to doctors. Our findings on
the provision of medicines information for type of main
product discussed were limited by the sample.
Conclusion
Information on indications and dosages were usually pro-
vided by pharmaceutical representatives in both Australia
and Malaysia. However, risk and harmful effects of medi-
cines were often missing in pharmaceutical representa-
tives’ presentations. This is a concern, as incomplete
medicines information may lead to misrepresentation of
the actual therapeutic value of the medicines and ignor-
ance of safety issues may ultimately negatively impact on
health outcomes.
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